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and TS. T1DM and T2DM-n.i reported better values of HRQoL
and T2DM-n.i better TS.
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OBJECTIVES: Patients play a major role in the management of
type 2 diabetes since this depends not only on medication but
also on behavioural modiﬁcations in areas such as nutrition,
physical activities and weight loss. Therefore, patients’ under-
standing of the disease and its management are particularly
important to ensure high compliance and reduce risk of late
complications. The aim of this project was to develop a tool for
clinical practice to 1) renew patient-clinician communication on
type 2 diabetes management; 2) reinforce patients’ motivation
by rectifying or perfecting their knowledge; and 3) agree
achievable micro-objectives between patients and clinicians.
METHODS: Face-to-face semi-structured interviews were con-
ducted with 10 adult type 2 diabetes patients by a psychologist
in parallel with interviews with 5 general practitioners,
involved in the management of type 2 diabetic patients. All
interviews were recorded and transcribed, in order to analyse
the content and organise it by domains. Based on these ﬁndings
and on feedback from experts, a ﬁrst version of the tool was
developed. This was tested using a cognitive interview method
with 5 type 2 diabetics, to assess the clarity, comprehension,
and relevance of each item as well as the overall acceptability
of the tool. RESULTS: Five major domains were identiﬁed as
playing a role in type 2 diabetes disease management: physical
activities, treatment, nutrition, knowledge of the disease and
knowledge of glycaemia issues. A speciﬁc module was devel-
oped around each of the 5 domains, drafting items using
patients’ verbatim expressions. The tool allows patients to
describe their beliefs, attitudes and priorities. The tool was
revised after the patient tests. CONCLUSIONS: This tool
should enhance patient-clinician communication on diabetes
management. By revealing patients’ beliefs, identifying their
goals, triggering positive changes, this tool could help clinicians
with the therapeutic education of patients. It will be tested in a
speciﬁc validation study.
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OBJECTIVES: Diabetes is a common, debilitating chronic illness
with multiple impacts on patients’ lives. Critical to understand-
ing these impacts is the effect of the treatment delivery system. In
diabetes multiple systems are available; however, a patient
reported outcomes (PRO) measure assessing impacts appropriate
for all systems is not available. As a result, impacts can’t be
compared across treatments and clinical decisions targeting treat-
ments to patient needs is hampered. A well developed PRO
measure appropriate across delivery systems is critical for future
research. The purpose of the study was to understand the full
spectrum of PRO issues and develop a measure of these impacts
across all delivery systems. METHODS: Qualitative data was
collected from literature, experts and patients and transcripts
thematically coded. Additionally, validation ﬁndings from four
previously developed diabetes PRO measures (ITSQ, Diab-
MedSat, Diabetes Productivity, Diabetes Symptom) were exam-
ined for relevance. Based on a synthesis of all information, a
conceptual model of the impact of treatment applicable to all
delivery systems was developed and a PRO measure generated.
RESULTS: A total of 143 patients in three countries (US, UK,
Australia) treated with the full range of treatment options (oral,
syringe, pen, inhaled, pump) were interviewed regarding the
impact of diabetes treatment on functioning, well-being and
health. Regardless of delivery system, common impacts of dia-
betes treatment were identiﬁed: psychological health, daily life
interference (home/work), treatment burden, device satisfaction,
perceived efﬁcacy and side effects. Key modiﬁers to this impact
(i.e., treatment history, occupation, activity level) and conse-
quences (i.e., compliance, poor productivity) were also identiﬁed.
Based on the conceptual model, a PRO impact measure (TRIM-
Diabetes) was generated with six discrete domains. CONCLU-
SIONS: The instrument development process, the full conceptual
model, and discussion of clinical implications will be presented.
This information should help clinicians identify key PRO issues
for diabetes, facilitate targeted treatments and allow for mean-
ingful measurement of treatment effect regardless of treatment
delivery system.
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OBJECTIVES: To develop concepts, domains and items for a
patient-reported outcome proﬁle measure that addresses the
behaviors, attitudes, and importance of self-managing diabetes in
patients with type 2 diabetes. This self-management proﬁle
complements traditional clinical outcomes to evaluate how
diabetes treatments improve self-management behaviors.
METHODS: We developed a conceptual model and conceptual
framework of patient self-management to support a patient-
reported self-management proﬁle. These models incorporate
treatment attributes identiﬁed through qualitative interviews
with patients and the review of the American Diabetes Associa-
tion (ADA) 2008 Standards of Medical Care in Diabetes. The
proﬁle consists of items measuring patient behaviors, feelings,
and attitudes about the importance of managing their blood
glucose, medication regimen, weight, eating, exercise, and
diabetes-related distress. Qualitative interviews were conducted
with patients with Type 2 diabetes managed with combinations
of lifestyle, oral and injectable therapy. Subjects were asked to
provide information on their most positive and problematic
experiences with treatment for their diabetes and their efforts to
manage their condition. Qualitative transcripts were coded by
like concepts and used with the ADA Standards to generate items
and develop the self management proﬁle. Additional patients
participated in cognitive interviews to address relevance and
clarity of items. RESULTS: Patients were enrolled from clinics
across the United States. Participants in the concept elicitation
interviews (n = 82) were 30–85 years of age (mean = 57.5);
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42.7% were female. A 16 item instrument was developed and
reﬁned using cognitive interviews (n = 26). The new instrument is
currently being evaluated for validity and sensitivity. CONCLU-
SIONS: Patient self-management of type 2 diabetes is a crucial
element of successful outcomes in both research studies and
clinical practice settings. The Diabetes Self-Management Proﬁle
will be useful for measuring the impact of different treatment
modalities on patients’ ability to manage the multiple aspects of
their Type 2 diabetes.
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OBJECTIVES: To validate the Human Growth Hormone Pref-
erence and Satisfaction Questionnaire (HGH-PSQ), a new instru-
ment for assessing preference for and satisfaction with HGH
treatment modalities. METHODS: Following IRB approval, the
initial instrument was pilot tested at 4 clinical sites specializing in
pediatric endocrinology. Clinicians, patients, and parents partici-
pated in assessing the properties, overall functionality, and com-
prehension of the instrument. Eligible patients completing the
instrument were children and adolescents 10–18 years old, and
were either new or established users of HGH. Face validity,
statistical validity, internal reliability, domain intercorrelations,
and test-retest reliability were assessed for each domain, as well
as for the entire instrument. RESULTS: Forty-nine patients and
their parents were administered the instrument, with 48 complet-
ing the retest. Following structured feedback and statistical
analysis, the ﬁnal instrument was reduced to 27 items in the
patient version and 30 items in the parent version, covering 5
domains of affect, non-interference, ease of administration/
preparation, pain, and overall satisfaction. Structured develop-
ment of the instrument with input from clinicians,
psychometricians, patients and their families ensured maximum
face validity. Variability and distribution in scores supported
statistical validity of the instrument. Strong internal reliability
was indicated, with Cronbach’s alpha of 0.85 and 0.89 for the
patient and parent versions, respectively. Intercorrelation coefﬁ-
cients for each domain with the overall instrument score demon-
strated convergent and discriminant validity. The instrument also
had good overall test-retest reliability, with correlations of 0.80
for patients and 0.73 for parents, with moderate to good coefﬁ-
cients for the individual domains. CONCLUSIONS: The HGH-
PSQ shows good psychometric properties and appears to be a
valid and reliable instrument to evaluate overall treatment satis-
faction with and patient preference for HGH delivery devices.
Future studies using larger samples of new users with HGH are
warranted to examine the sensitivity of the instrument to detect
differences among treatments.
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OBJECTIVES: Insulin is a potent drug available to manage dia-
betes and avoid serious complications and disease progression.
Unfortunately, psychological insulin resistance (PIR) is not
uncommon and negatively inﬂuences both initiation and com-
pliance with insulin treatment. Thus, understanding etiologies
of PIR is critical to ensure optimal diabetes management.
METHODS: Systematic literature review of peer reviewed jour-
nals using MEDLINE database including all articles (English)
from 1985–2007. The keywords and phrases used for the
search included psychological insulin resistance, type 1/2 dia-
betes, resistance to insulin therapy, insulin side effects/
complications, reluctance to treat, treatment refusal, barriers to
compliance, switching, racial/ethnic/cultural/gender issues/
barriers initiating insulin, patient reluctance, psychological
adjustment, needle/injection anxiety/phobia/fear, psycho-social
aspects, patient perceptions, acceptance/adherence and patient
preference. A total of 106 articles were reviewed. RESULTS:
Multiple etiologies of PIR were identiﬁed including patients’
beliefs and knowledge about diabetes/insulin, negative self per-
ceptions and attitudinal barriers, fear of side effects, complica-
tions from insulin use, social stigma and lifestyle adaptations
required by insulin use. Gender, socio-economics and culture
may modify this impact. Additionally, individual or physician
beliefs that one cannot comply with treatment or cope with
repeated blood tests, fear of hypoglycemia or weight gain and
physicians’ previous experience with insulin may also contrib-
ute to PIR. These etiological inﬂuences, both independently
and in combination, constitute patients’ PIR and may results
in compromised glucose control. CONCLUSIONS: PIR is
complex and multifaceted and plays an important, often
ignored role in diabetes management. This presentation will
review the full scope of PIR etiologies and discuss treatment
implications. Assisting health care professionals to better under-
standing PIR and tailor insulin treatment modalities accord-
ingly (e.g., with modern insulin analogues associated with less
weight gain and less hypoglycemia and/or insulin pen devices),
may greatly reduce patients’ PIR associated with using human-
insulin in vial and syringe.
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OBJECTIVES: Approximately 90% of the diabetes population
has type 2 diabetes, which has been predicted to become the
epidemic of the 21st century. Treatment satisfaction is not only an
important patient-reported outcome (PRO) but also a signiﬁcant
predictor of medication adherence, with implications for the
prevention of long-term complications, e.g. retinopathy, neuropa-
thy, nephropathy. The FDAhasmade recommendations regarding
the development and use of PRO measures. Our aim was to
identify treatment satisfaction questionnaires for use in non-
insulin-treated type 2 diabetes and scrutinize their development
history and psychometric properties. METHODS: We used a
PICO (population, intervention, competitor and outcome) strat-
egy to search Scopus from 2000 to present for relevant articles.
Key search terms included “type 2 diabet*” and “satisfact*”.
Following screening, speciﬁc searches for instrument names and
citation searches were then conducted.RESULTS:A total of 2154
abstracts were screened. Four treatment satisfaction instruments
were identiﬁed as designed for use in non-insulin-treated type 2
diabetes: the Diabetes Treatment Satisfaction Questionnaire
(DTSQ), the Diabetes Medication Satisfaction (Diab-MedSat)
questionnaire, the Diabetes Tablet Treatment Questionnaire
(DTTQ) and the Satisfaction with Oral Anti-Diabetic Agent Scale
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